SAN FRANCISCO, March 10, 2020 /PRNewswire/ — Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Nkarta, Inc. (“NKARTA”) for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support NKARTA’s antibody-based therapeutic discovery programs.
“TRIANNI is pleased to add NKARTA as a new licensee of the Trianni Mouse,” stated Matthias Wabl, Ph.D., TRIANNI’s President & CEO. “We are confident that combining TRIANNI’s powerful antibody discovery platform with NKARTA’s unique proprietary technology will facilitate NKARTA’s development of novel cell-based therapeutics.”
No financial details were disclosed.
About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com.
Contact: Trianni, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/trianni-inc-announces-license-agreement-with-nkarta-inc-for-the-trianni-mouse-301017398.html